Business Wire

NTHU Researchers Develop AI App for Generating Catchy Ads

18.3.2020 12:00:00 EET | Business Wire | Press release

Share

An NTHU interdisciplinary research team led by Associate Professor Wu Shan-hung of the Department of Computer Science, Associate Professor Liu Yi-wen of the Department of Electrical Engineering, and Chair Professor Chang Cheng-shang of the Institute of Communications Engineering has recently developed an automated system for the production of digital advertisements. Based on the information provided by the user, the system generates a variety of images and music, which can be fine-tuned to create the final product, thereby greatly reducing the time and cost of producing an advertisement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200318005022/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

A research team led by Wu Shan-hung (left) and Liu Yi-wen of NTHU has developed an AI App for generating catchy ads. (Photo: National Tsing Hua University)

Wu and Chang designed a conditional generative adversarial network (CGAN) application which generates an ad based on a large amount of related information harvested from the internet by using artificial intelligence (AI). Afterwards, all that remains to be done is to have an advertising specialist edit the ad and add the finishing touches.

Wu explained that the application performs a social network analysis which determines the most popular elements and user preferences to generate eye-catching digital advertisements and optimal screen layouts. For example, the user enters a photo of a bed set with a circle around the bed, and the system automatically generates a variety of ads highlighting the bed’s unique characteristics.

The application can also generate advertisements with models. For example, the user enters a photo of Keanu Reeves after circling certain features he wants to keep, such as the forehead and eyes, and the system will incorporate these features into a new image with similar characteristics.

Wu's team worked with the startup AppFinca to redesign the webpage for its app called “Flora.” After analysis, the team changed Flora's advertising slogan to “He grows trees, and you grow up,” and also came up with a lively color scheme to replace the rather drab one originally used for the page.

The transformation resulted in Flora shooting up to the top position in the rankings of the Free Productivity Tools of the Apple App Store for Taiwan, outranking even Gmail. AppFinca vice president Sun Zhen-wei said that the cost was only 60% of the original advertising fee.

The application developed by the research team also produces jingles. They collected 600 songs and used them to train the system to generate a jingle based on the lyrics and melody, and the result can be adjusted in terms of pitch, timbre, and rhythm. Even though the jingles generated by the application aren’t likely to be nominated for a Grammy Award, the system significantly speeds up the creative process.

The research team has already published a total of 19 articles on their research, and have also presented their results at various international conferences, including the Conference on Neural Information Processing Systems and the International Conference on Acoustics, Speech, and Signal Processing. They are also conducting negotiations with United Microelectronics, Asus, for commercial application of their system.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Hsueh
(886)3-5162006
hoyu@mx.nthu.edu.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye